Business Context and Reporting Period
The submitted text is a Form 10-Q for NeuroBo Pharmaceuticals, Inc., not Metavia Inc. It covers the quarter ended March 31, 2022, and was signed May 13, 2022. NeuroBo is a clinical-stage biotechnology company with programs targeting COVID-19, diabetic neuropathy, neurodegenerative disease, and cardiometabolic conditions.
- ANA001: Oral niclosamide formulation in a 60-subject U.S. Phase 2 COVID-19 trial; Phase 3 depends on Phase 2 results.
- NB-01: Development stopped on the prior regulatory pathway; orphan-drug and nutraceutical alternatives are being evaluated.
- NB-02: Further FDA IND work and first human trials postponed pending improved health and macroeconomic conditions; strategic partnering is under consideration.
- Gemcabene: Being evaluated for additional indications, including use with ANA001 for COVID-19.
Key Financial Metrics
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $0.9 million | $1.1 million |
| General and administrative expense | $2.0 million | $2.2 million |
| Total operating expenses | $2.875 million | $3.330 million |
| Net loss | $2.875 million | $3.324 million |
| Net loss per share | $0.11 | $0.15 |
| Net cash used in operating activities | $4.829 million | $6.141 million |
| Net cash from financing activities | None | $9.092 million |
| Cash at period end | $11.557 million | $13.035 million |
All dollar amounts above are based on the filing’s stated units and are rounded where presented in millions. Gross margin and operating margin are not meaningful because the company reported no revenue. Interest income was nominal in 2022 versus $6,000 in 2021, and no income tax provision was recorded.
At March 31, 2022, total assets were $13.461 million, total liabilities were $1.533 million, and stockholders’ equity was $11.928 million. Current liabilities were $1.496 million, compared with current assets of $13.264 million. The company reported no conventional debt; liabilities primarily consisted of accounts payable, accrued liabilities, and lease liabilities.
Common shares outstanding were 26,661,771 at March 31, 2022 and May 11, 2022. Outstanding warrants totaled 6,846,633, and stock options totaled 981,665 at quarter-end.
Material Changes Versus the Prior Comparable Period
- Total operating expenses declined by $455,000, or approximately 14%, primarily due to lower research and development, insurance, payroll, professional-fee, and overhead costs.
- Net loss improved by $449,000, or approximately 14%, from $3.324 million to $2.875 million.
- Cash used in operations decreased by $1.312 million, but the company had no financing proceeds in Q1 2022 compared with $9.092 million of net financing proceeds in Q1 2021.
- Cash declined by $4.830 million during Q1 2022, from $16.387 million to $11.557 million. The decrease included approximately $1.510 million used for prepaid expenses and other assets, principally related to annual insurance renewals.
- The accumulated deficit increased from $81.828 million at December 31, 2021 to $84.703 million at March 31, 2022.
- Stock-based compensation increased modestly to $207,000 from $187,000.
- The company granted 40,000 stock options and forfeited 33,334 options during the quarter. No options were exercised.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expects existing cash to fund operations into the fourth quarter of 2022 at the current level of scientific activity.
- The company expects to continue incurring net losses and negative operating cash flow and does not expect near-term revenue from product sales, collaborations, grants, or other sources.
- The filing states that substantial doubt exists regarding the company’s ability to continue as a going concern. Additional equity, debt, collaboration, licensing, or other financing will be required; equity financing could dilute shareholders, while debt financing could impose restrictive covenants.
- Management expected to complete the ANA001 Phase 2 trial in the second half of 2022, although low COVID-19 hospitalization levels could delay completion.
- COVID-19 and the war in Ukraine may affect clinical trials, particularly trial sites and service providers in Poland and Ukraine. The ultimate financial and operational effects remain uncertain.
- Potential contingent obligations include ANA merger milestone payments of up to $175.5 million, a 2.5% royalty on worldwide net sales of applicable niclosamide products, and additional YourChoice license milestones totaling $19.5 million. No related liabilities were recorded because the outcomes and funding requirements were not considered probable.
- Potential Gemcabene obligations include contingent value rights entitling holders to specified percentages of proceeds from future licensing or transfers, as well as Pfizer milestone payments of up to $37 million and future royalties. No related liabilities were recorded.
- Disclosure controls and procedures were determined to be ineffective as of March 31, 2022 because of material weaknesses involving segregation of duties, wire transfers, journal-entry review, clinical-trial accrual review, and excessive system administrator access. Remediation was in progress but not complete.
- The company terminated its Korea lease effective April 30, 2022 and terminated the 2018 equity incentive plan on May 11, 2022; no awards remained outstanding under that plan.
- No material legal proceedings were reported, and the filing states that no material changes were made to critical accounting policies or estimates during the quarter.
Facts an Investor Should Verify
- Confirm the issuer identity: the supplied metadata says Metavia Inc., while the filing identifies NeuroBo Pharmaceuticals, Inc. and ticker NRBO.
- Verify the expected cash runway into Q4 2022 and the company’s ability to obtain additional financing.
- Track ANA001 Phase 2 enrollment, timing, results, and any decision regarding a Phase 3 trial.
- Assess the viability and regulatory pathway for NB-01, NB-02, and Gemcabene after the announced development delays and strategic review.
- Monitor dilution risk from future equity offerings, the 6.85 million outstanding warrants, and stock options.
- Review remediation of the disclosed material weaknesses in internal control over financial reporting.
- Evaluate the potential magnitude and timing of contingent milestone, royalty, license, and contingent-value-right obligations.